Search results for "Adjuvant treatment"

showing 10 items of 16 documents

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

2020

Simple Summary The outcome for patients with rectal cancer has significantly improved over the last thirty years. Previously, local relapses in the pelvis occurred in more than one third of all patients with apparently localized tumors. Total mesorectal excision was the first step to improve local control by reducing local relapses to less than 5%. Preoperative radiation, either short-course or long-course with concurrent administration of chemotherapy, was a second important step for reducing local relapses to a minimum, even in locally advanced tumors where a clean surgical resection was not possible or would not be curative. Magnetic resonance imaging is a very useful tool for locoregion…

0301 basic medicineCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLocally advancedReviewlcsh:RC254-282law.inventionMetastasis03 medical and health sciencesMesorectal fascia0302 clinical medicineRandomized controlled triallawmedicinewatch and wait strategyChemotherapyPreoperative chemoradiotherapyPostoperative chemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-risk locally advanced rectal cancer; Total neoadjuvant treatment; Watch and wait strategyhigh-risk locally advanced rectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisRadiologybusinesstotal neoadjuvant treatmentCancers
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct

Place de l’imagerie dans l’évaluation de l’efficacité des traitements dans le cancer du sein

2010

Resume Cette revue decrit le role de differentes methodes d’imagerie pour evaluer la reponse au traitement dans le cancer du sein. Deux situations sont envisageables : celle de la chimiotherapie neoadjuvante du cancer du sein et celle des metastases. Beaucoup de donnees cliniques sont disponibles pour trois criteres : le volume de la tumeur, la captation du fluorodeoxyglucose mesuree en TEP et la perfusion de la tumeur evaluee soit par IRM dynamique, soit en TEP. La TEP au 2-18F fluoro-2-desoxy-D-glucose (FDG) permet la prediction de la reponse apres une ou deux cures de chimiotherapie. De nouvelles approches pourraient prochainement affiner le role de l’imagerie. Ainsi, la TEP a la thymidi…

GynecologyLight nucleusmedicine.medical_specialtyOptical imagingRadiological and Ultrasound TechnologyNeoadjuvant treatmentPhilosophyBiophysicsmedicineRadiology Nuclear Medicine and imagingHuman Epidermal Growth Factor Receptor 2Médecine Nucléaire
researchProduct

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national reg…

2021

Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006–2009; II)2010–2013; III)2014–2…

MaleSurvivalColorectal cancermedicine.medical_treatmentT stage030230 surgeryTNM0302 clinical medicineRegistriesStage (cooking)Rectal cancerAged 80 and overMargins of ExcisionGeneral MedicineMiddle AgedNeoadjuvant TherapySurvival Ratemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtyNeoadjuvant treatmentPrognosiRectum03 medical and health sciencesYoung AdultmedicineAdjuvant therapyHumansChemotherapyAgedNeoplasm StagingRetrospective StudiesChemotherapyRadiotherapybusiness.industryRectal NeoplasmsCancerChemoradiotherapy Adjuvantmedicine.diseaseSurgeryRadiation therapySpainT-stageSurgerybusinessFollow-Up StudiesForecasting
researchProduct

Exercise Adherence and Effect of Self-Regulatory Behavior Change Techniques in Patients Undergoing Curative Cancer Treatment: Secondary Analysis from…

2020

Introduction: Adherence to exercise interventions in patients with cancer is often poorly described. Further, it is unclear if self-regulatory behavior change techniques (BCTs) can improve exercise adherence in cancer populations. We aimed to (1) describe exercise adherence in terms of frequency, intensity, time, type (FITT-principles) and dropouts, and (2) determine the effect of specific self-regulatory BCTs on exercise adherence in patients participating in an exercise intervention during curative cancer treatment. Methods: This study was a secondary analysis using data from a Swedish multicentre RCT. In a 2×2 factorial design, 577 participants recently diagnosed with curable breast, col…

Malemedicine.medical_specialtyadjuvant treatmentexercise prescriptionphysical activitylcsh:RC254-282law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBehavior TherapySecondary analysismedicineHumansIn patientadherenceSjukgymnastikExercisePhysiotherapySport and Fitness Sciencesbusiness.industryIdrottsvetenskapbehavioral interventionCancerProstatic NeoplasmsBehavior change methodsResistance Training030229 sport scienceslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCancer treatmentPeer reviewExercise TherapyComplementary and alternative medicineVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesisExercise and Cancer TreatmentoncologyPhysical therapyExercise prescriptionbusinessResearch Articlebehavior change support
researchProduct

Breast cancer subtypes can be determinant in the decision making process to avoid surgical axillary staging: A retrospective cohort study.

2015

Abstract Introduction The need for performing axillary lymph-node dissection in early breast cancer when the sentinel lymph node (SLN) is positive has been questioned in recent years. The purpose of this study was to identify a low-risk subgroup of early breast cancer patients in whom surgical axillary staging could be avoided, and to assess the probability of having a positive lymph-node (LN). Methods We evaluated the cohort of 612 consecutive women affected by early breast cancer. We considered age, tumor size, histological grade, vascular invasion, lymphatic invasion and cancer subtype (Luminal A, Luminal B HER-2+, Luminal B HER-2−, HER-2+, and Triple Negative) as variables for univariat…

OncologyAdultmedicine.medical_specialtyLymphovascular invasionReceptor ErbB-2Sentinel lymph nodeClinical Decision-Makingbreast cancer axillary surgery sentinel lymph node biopsy adjuvant treatment biological prognostic factors.Breast NeoplasmsTriple Negative Breast NeoplasmsCohort StudiesBreast cancerInternal medicineMedicineHumansNeoplasm InvasivenessSettore SECS-S/05 - Statistica SocialeLymph nodeAgedNeoplasm StagingRetrospective StudiesGynecologyAged 80 and overbusiness.industrySentinel Lymph Node BiopsyAge FactorsCancerRetrospective cohort studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseSettore MED/18 - Chirurgia GeneraleExact testmedicine.anatomical_structureLymphatic MetastasisAxillaLymph Node ExcisionSurgeryFemalebusinessInternational journal of surgery (London, England)
researchProduct

SEOM clinical guideline for treatment of kidney cancer (2017)

2017

Abstract The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be consid…

OncologyCancer Researchmedicine.medical_specialtyCabozantinibhumanosRonyóClinical Guides in Oncologyurologic and male genital diseasesKidneylaw.inventionPazopanib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRenal cell carcinomalawInternal medicinemedicineHumans030212 general & internal medicineCàncerCarcinoma Renal CellCancerMolecular pathologyAdjuvant treatment of cancerneoplasias renalesSystemic therapybusiness.industrySunitinibCarcinomaCorrectionKidney cancerGeneral Medicinemedicine.diseaseKidney NeoplasmsOncologychemistry030220 oncology & carcinogenesisLocalized diseaseNivolumabbusinessKidney cancermedicine.drugTractament adjuvant del càncer
researchProduct

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

2012

Background In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed. Patients and methods We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPc…

Oncologymedicine.medical_specialtyEndoPredict geneAntineoplastic Agents HormonalReceptor ErbB-2Populationadjuvant treatmentBreast NeoplasmsKaplan-Meier EstimateAnastrozoleRisk AssessmentDisease-Free SurvivalBreast cancerInternal medicineBreast CancerexpressionAntineoplastic Combined Chemotherapy ProtocolsNitrilesmedicineHumanseducationSurvival analysisRetrospective Studieseducation.field_of_studybusiness.industryendocrine therapyAbsolute risk reductionRetrospective cohort studyHematologyOriginal ArticlesMiddle AgedTriazolesmedicine.diseasePrognosisChemotherapy regimenSurgeryTamoxifenTreatment OutcomeOncologyReceptors EstrogenChemotherapy AdjuvantPractice Guidelines as TopicFemaleBreast diseasebusinessRisk assessmentAnnals of Oncology
researchProduct

Therapiemonitoring mittels 2-[18F]-FDG-Positronenemissionstomographie nach neoadjuvanter Strahlenbehandlung des Mundhöhlenkarzinoms

2001

Die Kombination strahlentherapeutischer und chirurgischer Behandlungsschritte beim Mundhohlenkarzinom erfordert eine fruhe, objektive Bewertung des Bestrahlungserfolgs. Schlechtes radiotherapeutisches Ansprechverhalten verlangt die moglichst umgehende chirurgische Sanierung auch bei hohem Operations- und Narkoserisiko. Eine deutliche Remission unter Strahlentherapie kann dagegen die Fortsetzung der Bestrahlungsbehandlung begrunden. Die vorliegende Studie untersucht daher die Bewertung des Bestrahlungserfolgs anhand der durch Positronenemissionstomographie (PET) bestimmten Glukosestoffwechselaktivitat.

Radiation therapyOncologyEpidermoid carcinomabusiness.industryNeoadjuvant treatmentmedicine.medical_treatmentmedicineRadiology Nuclear Medicine and imagingNuclear medicinebusinessOral cavityStrahlentherapie und Onkologie
researchProduct